HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions

Thrombosis and Haemostasis

Volumn 103, Issue 1, 2010, Pages 83-93

  Kretz, Colin A ^a   Cuddy, Karl K ^a   Stafford, Alan R ^a   Fredenburgh, James C ^a   Roberts, Robin ^a   Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Aptamer; Cofactor activation; Prothrombinase; Thrombin; Thrombin generation assay

Indexed keywords

ANTICOAGULANT AGENT; APTAMER; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; HD1 PROTEIN; HEPARIN COFACTOR II; HIR 54-65 SO 3; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME;

ANTICOAGULANTS; ANTITHROMBINS; APTAMERS, NUCLEOTIDE; BINDING SITES; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FACTOR VA; FACTOR VIIIA; FEEDBACK, PHYSIOLOGICAL; HEPARIN COFACTOR II; HIRUDINS; HUMANS; KINETICS; OLIGOPEPTIDES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; PROTHROMBIN TIME; SULFATES; THROMBIN; THROMBOPLASTIN;

EID: 74249120395     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-04-0237     Document Type: Article

References (41)

1. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 2007; 282: 25416-25424.
2. van Dieijen G, Tans G, Rosing J, et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442.
3. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-10962.
4. van Rijn JLML, Govers-Riemslag JWP, Zwaal RFA, et al. Kinetic studies of prothombin activation: Effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry 1984; 23: 4557-4564.
5. Hemker HC, Al Dieri R, DE Smedt E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-561.
6. Adams TE, Huntington JA. Thrombin-cofactor interactions: structural insights into regulatory mechanisms. Arterioscler Throm Vasc Biol 2006; 26: 1738-1745.
7. Stubbs MT, Bode W. A player of many parts - The spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
8. Nogami K, Zhou Q, Myles T, et al. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J Biol Chem 2005; 280: 18476-18487.
9. Bukys MA, Orban T, Kim PY, et al. The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII. J Biol Chem 2006; 281: 18569-18580.
10. Griffin LC, Toole JJ, Leung LLK. The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene 1993; 137: 25-31.
11. Naski MC, Fenton JWI, Maraganore JM, et al. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen. J Biol Chem 1990; 265: 13484-13489.
12. DiMaio J, Gibbs B, Munn D, et al. Bifunctional thrombin inhibitors based on the sequence of hirudin45-65. J Biol Chem 1990; 265: 21698-21703.
13. Thurieau C, Simonet S, Paladino J, et al. New Nm?-guanidinobenzoyl derivatives of hirudin-54-65 containing stabilized carboxyl or phosphoryl groups on the side chain of phenylalanine-63. J Med Chem 1994; 37: 625-629.
14. Kretz CA, Stafford AR, Fredenburgh JC, et al. HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. J Biol Chem 2006; 281: 37477-37485.
15. Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 1979; 18: 4419-4425.
16. Barenholz Y, Gibbes D, Litman BJ, et al. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-2810.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
18. Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138.
19. Becker DL, Fredenburgh JC, Stafford AR, et al. Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv Exp Med Biol 1997; 425: 55-66.
20. Kelinbaum DG, Kupper LL, Muller KE, et al. Applied Regression Analysis and Other Miltivariable Methods, 2nd Ed., PWS, 1988, Boston, MA, USA
21. Rezaie AR. Tryptophan 60-D in the B-insertion loop of thrombin modulates the thrombin antithrombin reaction. Biochemistry 1996; 35: 1918-1924.
22. Pospisil CH, Stafford AR, Fredenburgh JC, et al. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem 2003; 278: 21584-21591.
23. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-23125.
24. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hemat 2004; 11: 170-175.
25. Al Dieri R, Alban S, Beguin S, et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-1401.
26. Anderson PJ, Nesset A, Dharmawardana KR, et al. Characterization of proexosite I on prothrombin. J Biol Chem 2000; 275: 16428-16434.
27. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152.
28. Mann KG, Brummel-Ziedins K, Orfeo T, et al. Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108-117.
29. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-888.
30. Wakabayashi H, Fay PJ. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa. J Biol Chem 2008; 283: 11645-11651.
31. Wakabayashi H, Varfaj F, Deangelis J, et al. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood 2008; 112: 2761-2769.
32. Ovanesov MV, Ananyeva NM, Panteleev MA, et al. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost 2005; 3: 321-331.
33. Anderson PJ, Nesset A, Dharmawardana KR, et al. Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation. J Biol Chem 2000; 275: 16435-16442.
34. Thorelli E, Kaufman RJ, Dahlback B. Cleavage requirements of factor V in tissuefactor induced thrombin generation. Thromb Haemost 1998; 80: 92-98.
35. Allen GA, Wolberg AS, Oliver JA, et al. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-413.
36. Butenas S, Orfeo T, Brummel-Ziedins KE, et al. Influence of bivalirudin on tissue factor-triggered coagulation. Blood Coag Fibrinolysis 2007; 18: 407-414.
37. Croy CH, Koeppe JR, Bergqvist S, et al. Allosteric changes in solvent accessibility observed in thrombin upon active site occupation. Biochemistry 2004; 43: 5246-5255.
38. Duffy EJ, Angliker H, Le Bonniec BF, et al. Allosteric modulation of the activity of thrombin. Biochem J 1997; 321: 361-365.
39. Fredenburgh JC, Stafford AR, Weitz JI. Evidence for allosteric linkage between exosites 1 and 2 of thrombin. J Biol Chem 1997; 272: 25493-25499.
40. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
41. Sanchez C, Alessi MC, Saut N, et al. Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. J Thromb Haemost 2008; 6: 1975-1977.